Ping A Chen

US Patent:

6653304, Nov 25, 2003

Filed:

Feb 8, 2001

Appl. No.:

09/779109

Inventors:

Katerina Leftheris - Skillman NJ
Hong Wu - Lawrenceville NJ
Stephen Wrobleski - Whitehouse Station NJ
Ping Chen - Belle Mead NJ
John Hynes - Washington Crossing PA
John Tokarski - Princeton NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D40312

US Classification:

5142328, 514292, 544126, 546 81

Abstract:

Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.

US Patent:

6916809, Jul 12, 2005

Filed:

Dec 20, 2002

Appl. No.:

10/325009

Inventors:

Ping Chen - Belle Mead NJ, US
Edwin J. Iwanowicz - West Windsor NJ, US
Scott H. Watterson - Pennington NJ, US
Henry Gu - Bordentown NJ, US
Yufen Zhao - Pennington NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D471/14
C07D471/04
A61K031/4375
A61P019/02
A61P017/06

US Classification:

5142305, 51425505, 514256, 514293, 544105, 544333, 544405, 544 60, 544126, 544361, 544250, 546 81, 540575

Abstract:

Compounds having the formula (I), wherein Ris selected from H, OH and NH; Ris selected from ═O and ═S; W is —C(═O)—, —S(═O)—, or —S(O)—; or W may be —CH— if X is —C(═O)—; X is selected from —CH—, —N(R)—, and —O—, except that when W is —CH—, X is —C(═O)—; Y is a bond or —C(R)(R)—; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X, X, X, X, X, X, X, X, X, Xand Xare selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.

US Patent:

7514435, Apr 7, 2009

Filed:

Nov 16, 2006

Appl. No.:

11/560378

Inventors:

Ping Chen - Belle Mead NJ, US
Yufen Zhao - Pennington NJ, US
Brian E. Fink - Yardley PA, US
Soong-Hoon Kim - Titusville NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/06
A61K 31/4412
A61K 31/4427
A61K 31/53
A61P 19/02
A61P 35/00

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as antiproliferative agents.

US Patent:

8530487, Sep 10, 2013

Filed:

Jan 29, 2010

Appl. No.:

12/696618

Inventors:

Xinyuan Wu - Newton MA, US
Spencer David Kimball - East Windsor NJ, US
Ping Chen - Franklin Park NJ, US
Ding Zhou - Shanghai, CN
Shaoping Peng - Shanghai, CN

Assignee:

Hydra Biosciences, Inc. - Cambridge MA

International Classification:

A01N 43/54
A61K 31/505
C07D 239/00
C07D 471/00

US Classification:

514267, 544250

Abstract:

Compounds and compositions for treating disorders related to TRPA1 are described herein.

US Patent:

20060155125, Jul 13, 2006

Filed:

Dec 21, 2005

Appl. No.:

11/314794

Inventors:

Ping Chen - Belle Mead NJ, US
Derek Norris - Pennington NJ, US
Ashvinikumar Gavai - Princeton Junction NJ, US

International Classification:

C07D 487/02
C07D 487/04

US Classification:

544184000, 544279000, 544280000

Abstract:

The present invention provides a process for preparing compounds of formula (IV) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

US Patent:

20130123237, May 16, 2013

Filed:

Feb 23, 2012

Appl. No.:

13/812536

Inventors:

Rajan Anand - Fanwood NJ, US
James M. Apgar - Highland Park NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Lin Chu - Scotch Plains NJ, US
Vincent J. Colandrea - North Brunswick NJ, US
Guizhen Dong - Dayton NJ, US
James F. Dropinski - Colts Neck NJ, US
Danqing Feng - Green Brook NJ, US
Jacqueline D. Hicks - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Alexander J. Kim - Morganville NJ, US
Kenneth J. Leavitt - Plainsboro NJ, US
Bing Li - Towaco NJ, US
Xiaoxia Qian - New York NY, US
Iyassu Sebhat - Jersey City NJ, US
Lan Wei - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Zhicai Wu - Montvale NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/5377
A61K 31/437
A61K 31/4985
A61K 31/351
A61K 31/397
A61K 31/4412
C07D 471/04
A61K 31/496

US Classification:

51421021, 546118, 514303, 544362, 51425304, 544127, 5142342

Abstract:

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

US Patent:

20130203786, Aug 8, 2013

Filed:

May 16, 2011

Appl. No.:

13/643121

Inventors:

Jacqueline D. Hicks - Scotch Plains NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Xiaoxia Qian - New York NY, US
Robert R. Wilkening - Maplewood NJ, US

International Classification:

C07D 487/04
A61K 31/506
A61K 45/06
A61K 31/519
A61K 31/437
A61K 31/4162
A61K 31/4439

US Classification:

5142641, 5483565, 514407, 514275, 544331, 5462757, 514338, 544280, 5142651, 514303, 546119, 544279

Abstract:

The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20140080884, Mar 20, 2014

Filed:

Jun 25, 2012

Appl. No.:

14/118998

Inventors:

Itzia Arroyo - Union NJ, US
Davida Krueger - Brooklyn NY, US
Ping Chen - Edison NJ, US
Aaron Moment - Middletown NJ, US
Tesfaye Biftu - Freehold NJ, US
Faye Sheen - Hoddesdon, GB
Yanfeng Zhang - Panan, Zhejiang, CN

Assignee:

Merck Sharp & Dohme Ltd. - Hoddesdon, Hertfordshire
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04

US Classification:

514407, 5483605

Abstract:

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.